1. Home
  2. LXEH vs CTSO Comparison

LXEH vs CTSO Comparison

Compare LXEH & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lixiang Education Holding Co. Ltd.

LXEH

Lixiang Education Holding Co. Ltd.

N/A

Current Price

$0.23

Market Cap

6.5M

Sector

Real Estate

ML Signal

N/A

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

N/A

Current Price

$0.77

Market Cap

45.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LXEH
CTSO
Founded
2001
1997
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
45.7M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
LXEH
CTSO
Price
$0.23
$0.77
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
669.9K
67.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,503,908.00
Revenue This Year
N/A
$7.29
Revenue Next Year
N/A
$8.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
48.53
52 Week Low
$0.18
$0.60
52 Week High
$50.08
$1.39

Technical Indicators

Market Signals
Indicator
LXEH
CTSO
Relative Strength Index (RSI) 50.13 54.78
Support Level $0.18 $0.62
Resistance Level $0.28 $0.84
Average True Range (ATR) 0.03 0.04
MACD 0.00 0.01
Stochastic Oscillator 25.09 59.46

Price Performance

Historical Comparison
LXEH
CTSO

About LXEH Lixiang Education Holding Co. Ltd.

Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: